Abstract
The literature concerning the design of large-scale high-throughput multiplexed genotyping assays for profiling tumour somatic mutations, and studies of their validation and prospective clinical use in guiding targeted therapies, is reviewed. Reports of the design and development of genotyping approaches for the simultaneous detection of numerous oncogenic driver mutations in many known cancer genes first appeared in the literature between 2007 and 2010. Retrospective studies of the detection of somatic mutations in a representative series of human tumour specimens has provided evidence of analytical validity as well as technical accuracy and reliability. Six prospective clinical studies reported since 2011 have generated evidence supporting the clinical validity of these genotyping approaches in identifying tumour somatic mutations in cancer patients in a way that could guide their treatment options. Currently, over forty different targeted drug therapies are approved for clinical use in treating cancer that therapeutically address over sixty different cancer- associated genes and hundreds of individual oncogenic driver mutations. This expanding list of targetable cancer genes and driver mutations are now candidates for inclusion in customised genotyping designs for future clinical evaluation in guiding targeted cancer therapy.
Keywords: Cancer, mutation profiling, targeted therapies, tumour genotyping.
Current Cancer Therapy Reviews
Title:Tumour Mutation Profiling with High-throughput Multiplexed Genotyping: A Review of its Use for Guiding Targeted Cancer Therapy
Volume: 9 Issue: 4
Author(s): Mark J. McKeage, Phillip Shepherd, Masato Yozu and Donald R. Love
Affiliation:
Keywords: Cancer, mutation profiling, targeted therapies, tumour genotyping.
Abstract: The literature concerning the design of large-scale high-throughput multiplexed genotyping assays for profiling tumour somatic mutations, and studies of their validation and prospective clinical use in guiding targeted therapies, is reviewed. Reports of the design and development of genotyping approaches for the simultaneous detection of numerous oncogenic driver mutations in many known cancer genes first appeared in the literature between 2007 and 2010. Retrospective studies of the detection of somatic mutations in a representative series of human tumour specimens has provided evidence of analytical validity as well as technical accuracy and reliability. Six prospective clinical studies reported since 2011 have generated evidence supporting the clinical validity of these genotyping approaches in identifying tumour somatic mutations in cancer patients in a way that could guide their treatment options. Currently, over forty different targeted drug therapies are approved for clinical use in treating cancer that therapeutically address over sixty different cancer- associated genes and hundreds of individual oncogenic driver mutations. This expanding list of targetable cancer genes and driver mutations are now candidates for inclusion in customised genotyping designs for future clinical evaluation in guiding targeted cancer therapy.
Export Options
About this article
Cite this article as:
McKeage J. Mark, Shepherd Phillip, Yozu Masato and R. Love Donald, Tumour Mutation Profiling with High-throughput Multiplexed Genotyping: A Review of its Use for Guiding Targeted Cancer Therapy, Current Cancer Therapy Reviews 2013; 9 (4) . https://dx.doi.org/10.2174/157339470904140418093822
DOI https://dx.doi.org/10.2174/157339470904140418093822 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry Stem cells contributing to postnatal skeletogenesis in the mouse bone marrow
Current Stem Cell Research & Therapy A Brief Evaluation of Tumor Imaging in Mice with 99mTc-glucarate Including a Comparison with 18F-FDG
Current Radiopharmaceuticals Identification of Phosphoproteins and their Impact as Biomarkers in Cancer Therapeutics
Current Signal Transduction Therapy Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy
Current Cancer Drug Targets Celastrus Orbiculatus Extract Potentiates the Sensitivity of Cisplatin Via Caspase-Depenent Apoptosis in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Graphical Abstracts:
Central Nervous System Agents in Medicinal Chemistry Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design Targeting the Ubiquitin-Proteasome Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Ion Channels and Epilepsy
Current Pharmaceutical Design Polyunsaturated Fatty Acids and their Metabolites in Neural Development and Implications for Psychiatric Disorders
Current Psychopharmacology Investigation of in Vitro Release Dynamics of Cisplatin from Genipin Crosslinked Gelatin Nanocarriers
Drug Delivery Letters Protein Kinase C Isozymes as Potential Targets for Anticancer Therapy
Current Cancer Drug Targets Synthesis and Antitumoral Evaluation of 7-chloro-4-quinolinylhydrazones Derivatives
Medicinal Chemistry Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy Apoptosis in Drug Response
Current Pharmacogenomics The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment
Current Medicinal Chemistry Recent Advances in Metal-Organic Frameworks as Anticancer Drug Delivery Systems: A Review
Anti-Cancer Agents in Medicinal Chemistry Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry